Therapeutic anticoagulation (Heparin) in the management of severe COVID-19 patients
24 December 2020
Therapeutic doses of either unfractionated heparin (UFH) or subcutaneous low molecular weight heparin (LMWH) should not be offered in the treatment of patients with COVID-19, unless there is a standard indication for therapeutic anti-coagulation, such as the acute management of acute deep vein thromboses or pulmonary emboli, or as part of a clinical trial.
Continue to use pharmacological VTE prophylaxis in COVID-19 pneumonia, unless contraindicated, with a standard prophylactic dose (for acutely ill medical patients) of low molecular weight heparin (LMWH).
ENDS